EDITORIAL article
Front. Immunol.
Sec. Immunological Tolerance and Regulation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1644057
This article is part of the Research TopicCommunity Series in Autoantibodies: Volume IIView all 12 articles
In volume II of the Research Topic on "Autoantibodies", the impact of autoantibodies in patients with autoimmune skin diseases.
Provisionally accepted
- 2nd Dermatology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
patients with autoimmune skin diseases is further discussed.Autoimmune bullous diseases (AIBDs) are a group of rare, chronic disorders characterized by the formation of bullae and erosions on the skin and/or mucous membranes. They result from an immune system attack on structural components of the skin that maintain cell-tocell or cell-to-basement membrane adhesion. Pemphigus vulgaris, bullous pemphigoid and epidermolysis bullosa acquisita are some of the main representatives of AIBDs.Previously, Eming et al. introduced a novel desmoglein 3 (Dsg3) EC5-binding antibody, termed 2G4, which may serve as a superior tool for various analyses related to PV. The aim of their recent study was to establish and validate standardized procedures to produce 2G4 IgG, enabling its use as a consistent and reliable tool in pemphigus research. This approach aims to facilitate the generation of comparable, high-quality data across different laboratory
Keywords: Pemphigus, Hidradenitis suppurativa (HS), Bullous pemhigoid, Bullous disease, Epidermolysis Bullosa
Received: 09 Jun 2025; Accepted: 20 Jun 2025.
Copyright: © 2025 Kyriakou and Patsatsi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Aikaterini Kyriakou, 2nd Dermatology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.